Actavis to buy Forest for $25 billion
21-02-2014
Forest Laboratories, a subsidiary of Allergan, has failed in its attempt to overturn a district court ruling in its patent battle with Teva.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Forest Laboratories, Teva, patent, Alzheimer’s, Allergan, Namenda XR
